Healthcare provider profile · identity verified

Ronald Ammon, MD

Internal Medicine · MONTROSE, NY · NPI 1477695310

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Furosemide	Furosemide	377	45
Atorvastatin Calcium	Atorvastatin Calcium	359	47
Eliquis	Apixaban	352	29
Tamsulosin Hcl	Tamsulosin Hcl	238	33
Amlodipine Besylate	Amlodipine Besylate	222	34
Metoprolol Succinate	Metoprolol Succinate	216	26
Pantoprazole Sodium	Pantoprazole Sodium	210	29
Levothyroxine Sodium	Levothyroxine Sodium	196	28
Omeprazole	Omeprazole	168	24
Finasteride	Finasteride	135	17
Lisinopril	Lisinopril	125	17
Mirtazapine	Mirtazapine	123	21
Losartan Potassium	Losartan Potassium	108	15
Metoprolol Tartrate	Metoprolol Tartrate	107	15
Sertraline Hcl	Sertraline Hcl	107	12
Gabapentin	Gabapentin	106	14
Duloxetine Hcl	Duloxetine Hcl	86	12
Potassium Chloride	Potassium Chloride	82	18
Metformin Hcl	Metformin Hcl	80	11
Trazodone Hcl	Trazodone Hcl	80	12
Escitalopram Oxalate	Escitalopram Oxalate	75	suppressed
Lactulose	Lactulose	73	16
Latanoprost	Latanoprost	71	13
Donepezil Hcl	Donepezil Hcl	67	12
Silver Sulfadiazine	Silver Sulfadiazine	67	26
Memantine Hcl	Memantine Hcl	62	suppressed
Levetiracetam	Levetiracetam	59	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	58	11
Incruse Ellipta	Umeclidinium Bromide	56	suppressed
Xarelto	Rivaroxaban	56	suppressed
Hydralazine Hcl	Hydralazine Hcl	54	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	51	15
Carbidopa-Levodopa	Carbidopa/Levodopa	46	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	46	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	46	suppressed
Aripiprazole	Aripiprazole	45	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	44	suppressed
Carvedilol	Carvedilol	43	suppressed
Allopurinol	Allopurinol	42	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	42	suppressed
Fluticasone Propionate	Fluticasone Propionate	40	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	35	suppressed
Humulin R	Insulin Regular, Human	35	suppressed
Montelukast Sodium	Montelukast Sodium	35	suppressed
Torsemide	Torsemide	35	suppressed
Clopidogrel	Clopidogrel Bisulfate	34	suppressed
Olanzapine	Olanzapine	34	suppressed
Citalopram Hbr	Citalopram Hydrobromide	32	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	30	suppressed
Ketoconazole	Ketoconazole	30	12
Breo Ellipta	Fluticasone/Vilanterol	29	suppressed
Novolog	Insulin Aspart	29	suppressed
Novolog Flexpen	Insulin Aspart	29	suppressed
Atenolol	Atenolol	28	suppressed
Digoxin	Digoxin	28	suppressed
Dorzolamide Hcl	Dorzolamide Hcl	28	suppressed
Timolol Maleate	Timolol Maleate	28	suppressed
Travoprost	Travoprost	28	suppressed
Hydrocortisone	Hydrocortisone	27	suppressed
Novolin 70-30	Insulin Nph Hum/Reg Insulin Hm	27	suppressed
Spironolactone	Spironolactone	25	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	24	suppressed
Lorazepam	Lorazepam	23	suppressed
Memantine Hcl Er	Memantine Hcl	23	suppressed
Nyamyc	Nystatin	23	suppressed
Prednisone	Prednisone	23	suppressed
Ramipril	Ramipril	23	suppressed
Vascepa	Icosapent Ethyl	23	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	22	suppressed
Tradjenta	Linagliptin	22	suppressed
Buspirone Hcl	Buspirone Hcl	21	suppressed
Calcitonin-Salmon	Calcitonin,salmon,synthetic	21	suppressed
Calcitriol	Calcitriol	21	suppressed
Ipratropium Bromide	Ipratropium Bromide	21	suppressed
Lamotrigine	Lamotrigine	21	suppressed
Nystatin	Nystatin	21	suppressed
Albuterol Sulfate	Albuterol Sulfate	20	11
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Mupirocin	Mupirocin	19	11
Paroxetine Hcl	Paroxetine Hcl	19	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	18	suppressed
Divalproex Sodium	Divalproex Sodium	18	suppressed
Rivastigmine	Rivastigmine	18	suppressed
Bicalutamide	Bicalutamide	17	suppressed
Ezetimibe	Ezetimibe	17	suppressed
Terazosin Hcl	Terazosin Hcl	17	suppressed
Entresto	Sacubitril/Valsartan	16	suppressed
Jardiance	Empagliflozin	16	suppressed
Labetalol Hcl	Labetalol Hcl	16	suppressed
Myrbetriq	Mirabegron	16	suppressed
Namzaric	Memantine Hcl/Donepezil Hcl	16	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	15	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	15	suppressed
Simvastatin	Simvastatin	15	suppressed
Ssd	Silver Sulfadiazine	15	suppressed
Azithromycin	Azithromycin	14	13
Colchicine	Colchicine	14	suppressed
Folic Acid	Folic Acid	14	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	14	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	14	suppressed
Bupropion Hcl Sr	Bupropion Hcl	13	suppressed
Combigan	Brimonidine Tartrate/Timolol	13	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	13	suppressed
Procrit	Epoetin Alfa	13	suppressed
Verapamil Sr	Verapamil Hcl	13	suppressed
Vyzulta	Latanoprostene Bunod	13	suppressed
Advair Diskus	Fluticasone Propion/Salmeterol	12	suppressed
Baclofen	Baclofen	12	suppressed
Ezetimibe-Simvastatin	Ezetimibe/Simvastatin	12	suppressed
Febuxostat	Febuxostat	12	suppressed
Levetiracetam Er	Levetiracetam	12	suppressed
Primidone	Primidone	12	suppressed
Amiodarone Hcl	Amiodarone Hcl	11	suppressed
Midodrine Hcl	Midodrine Hcl	11	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	11	suppressed
Risperidone	Risperidone	11	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error